163 related articles for article (PubMed ID: 31146385)
21. Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression.
Kondo T; Zheng L; Liu W; Kurebayashi J; Asa SL; Ezzat S
Cancer Res; 2007 Jun; 67(11):5461-70. PubMed ID: 17545628
[TBL] [Abstract][Full Text] [Related]
22. A Pro253Arg mutation in fibroblast growth factor receptor 2 (Fgfr2) causes skeleton malformation mimicking human Apert syndrome by affecting both chondrogenesis and osteogenesis.
Yin L; Du X; Li C; Xu X; Chen Z; Su N; Zhao L; Qi H; Li F; Xue J; Yang J; Jin M; Deng C; Chen L
Bone; 2008 Apr; 42(4):631-43. PubMed ID: 18242159
[TBL] [Abstract][Full Text] [Related]
23. Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer.
Chang J; Wang S; Zhang Z; Liu X; Wu Z; Geng R; Ge X; Dai C; Liu R; Zhang Q; Li W; Li J
Oncotarget; 2015 Feb; 6(4):2009-22. PubMed ID: 25576915
[TBL] [Abstract][Full Text] [Related]
24. Neural cell adhesion molecule-stimulated neurite outgrowth depends on activation of protein kinase C and the Ras-mitogen-activated protein kinase pathway.
Kolkova K; Novitskaya V; Pedersen N; Berezin V; Bock E
J Neurosci; 2000 Mar; 20(6):2238-46. PubMed ID: 10704499
[TBL] [Abstract][Full Text] [Related]
25. Upregulation of EphB3 in gastric cancer with acquired resistance to a FGFR inhibitor.
Lee SY; Na YJ; Jeong YA; Kim JL; Oh SC; Lee DH
Int J Biochem Cell Biol; 2018 Sep; 102():128-137. PubMed ID: 30044964
[TBL] [Abstract][Full Text] [Related]
26. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
[TBL] [Abstract][Full Text] [Related]
27. Activating somatic FGFR2 mutations in breast cancer.
Reintjes N; Li Y; Becker A; Rohmann E; Schmutzler R; Wollnik B
PLoS One; 2013; 8(3):e60264. PubMed ID: 23527311
[TBL] [Abstract][Full Text] [Related]
28. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
[TBL] [Abstract][Full Text] [Related]
29. Dexamethasone inhibits basic fibroblast growth factor-stimulated gastric epithelial cell proliferation.
Luo JC; Lin HY; Lu CL; Wang LY; Chang FY; Lin HC; Huang YC; Ng KM; Chi CW; Lee SD
Biochem Pharmacol; 2008 Oct; 76(7):841-9. PubMed ID: 18692028
[TBL] [Abstract][Full Text] [Related]
30. Activating FGFR2-RAS-BRAF mutations in ameloblastoma.
Brown NA; Rolland D; McHugh JB; Weigelin HC; Zhao L; Lim MS; Elenitoba-Johnson KS; Betz BL
Clin Cancer Res; 2014 Nov; 20(21):5517-26. PubMed ID: 24993163
[TBL] [Abstract][Full Text] [Related]
31. Extracellular Signal-Regulated Kinases 1 and 2 Phosphorylate Gab2 To Promote a Negative-Feedback Loop That Attenuates Phosphoinositide 3-Kinase/Akt Signaling.
Zhang X; Lavoie G; Méant A; Aubert L; Cargnello M; Haman A; Hoang T; Roux PP
Mol Cell Biol; 2017 Apr; 37(7):. PubMed ID: 28096188
[TBL] [Abstract][Full Text] [Related]
32. Mouse FLRT2 interacts with the extracellular and intracellular regions of FGFR2.
Wei K; Xu Y; Tse H; Manolson MF; Gong SG
J Dent Res; 2011 Oct; 90(10):1234-9. PubMed ID: 21765038
[TBL] [Abstract][Full Text] [Related]
33. FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review).
Katoh Y; Katoh M
Int J Mol Med; 2009 Mar; 23(3):307-11. PubMed ID: 19212647
[TBL] [Abstract][Full Text] [Related]
34. Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer.
Lei H; Deng CX
Int J Biol Sci; 2017; 13(9):1163-1171. PubMed ID: 29104507
[TBL] [Abstract][Full Text] [Related]
35. Cell type-specific importance of ras-c-raf complex association rate constants for MAPK signaling.
Kiel C; Serrano L
Sci Signal; 2009 Jul; 2(81):ra38. PubMed ID: 19638615
[TBL] [Abstract][Full Text] [Related]
36. A novel FGFR2 mutation in tyrosine kinase II domain, L617F, in Crouzon syndrome.
Suh YJ; Bae HS; Choi JY; Lee JH; Kim MJ; Kim S; Ryoo HM; Baek SH
J Cell Biochem; 2014 Jan; 115(1):102-10. PubMed ID: 23913723
[TBL] [Abstract][Full Text] [Related]
37. Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells.
Moffa AB; Tannheimer SL; Ethier SP
Mol Cancer Res; 2004 Nov; 2(11):643-52. PubMed ID: 15561780
[TBL] [Abstract][Full Text] [Related]
38. Osteoblast proliferation or differentiation is regulated by relative strengths of opposing signaling pathways.
Raucci A; Bellosta P; Grassi R; Basilico C; Mansukhani A
J Cell Physiol; 2008 May; 215(2):442-51. PubMed ID: 17960591
[TBL] [Abstract][Full Text] [Related]
39. Negative feedback regulation of the ERK1/2 MAPK pathway.
Lake D; Corrêa SA; Müller J
Cell Mol Life Sci; 2016 Dec; 73(23):4397-4413. PubMed ID: 27342992
[TBL] [Abstract][Full Text] [Related]
40. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
Phuchareon J; McCormick F; Eisele DW; Tetsu O
Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3855-63. PubMed ID: 26150526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
